Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study - Top-Institutions - MDSpire

Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study

  • By

  • Yang-Wei Cai

  • Jing-Wei Gao

  • Mao-Xiong Wu

  • Ze-Gui Huang

  • Guang-Hong Liao

  • Chuan-Rui Zeng

  • Pin-Ming Liu

  • Yang-Xin Chen

  • Jing-Feng Wang

  • Hai-Feng Zhang

  • November 13, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Cardio-Oncology
    • Oncology
    • Cardiology
    • Epidemiology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Cardio-Oncology
    • Oncology
    • Cardiology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Cardio-Oncology
    • Preventive Medicine

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Cardio-Oncology
    • Epidemiology

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Oncology
    • Cardio-Oncology
    • Preventive Medicine

Original Source(s)

Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study

  • by Yang-Wei Cai, Jing-Wei Gao, Mao-Xiong Wu, Ze-Gui Huang, Guang-Hong Liao, Chuan-Rui Zeng, Pin-Ming Liu, Yang-Xin Chen, Jing-Feng Wang, Hai-Feng Zhang

  • November 13, 2025

Related Content

Transcriptomic signatures and immune microenvironment of acute rejection after heart transplantation: an integrated bioinformatics analysis

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care